Bronchitis Treatment Market Size, Share & Industry Analysis, By Types (Chronic Bronchitis, Acute Bronchitis), By Drug Class (Antibiotics, Anti-Inflammatory Drugs, Bronchodilators, Mucolytic), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmaceutical Stores) and Regional Forecast, 2024-2032

Bronchitis is a medical condition that leads to inflammation of airways in the lungs (bronchial tubes), which cause coughing, generally with mucus. Symptoms of bronchitis include cough with mucus, dyspnea (shortness of breath), a whistling sound made while breathing, and chest pain. There are two basic types of bronchitis, acute and chronic. In developed as well as in developing countries, bronchitis is one of the most frequent respiratory diseases observed. The factors like smoking, bacterial infections, and repeated cold & flu that stimulate bronchitis are expected to drive the bronchitis treatment market growth.

Cigarette smoking is the most prominent cause of bronchitis and is likely to boost the market growth during the forecast period. According to American Lung Association (ALA) 2019, about 85 to 90 percent of all chronic obstructive pulmonary disease (COPD) cases are caused by cigarette smoking, which weakens the lung's defense against infections, narrow air passages, and cause swelling in the air tube. Moreover, an increase in the prevalence of COPD, which includes bronchitis majorly, is expected to boost the growth of the market. As per the World Health Organization (WHO) in 2017, approximately 251 million people in the world were likely to have COPD. It was also projected that in 2015, COPD caused 5% of all deaths globally. Furthermore, rising awareness and demand for safe & efficient treatment options related to bronchitis treatment & diagnosis expected to propel the market growth. Other risk factors such as a rising level of chemical pollutants, gastric reflux, occupational hazards like exposure to irritants such as chemicals, fumes, dust, and pollution are also likely to fuel the market growth.

However, stringent regulations regarding the release of drugs and the cost of approval are likely to hinder the market growth. 

Key Market Driver -

Cigarette smoking and an increase in the prevalence of bronchitis.

Key Market Restraint -

Stringent regulatory guidelines and high cost of drug approval.

Market Segmentation:

The global bronchitis treatment market can be segmented on the basis of types, drug class, distribution channel, and region. Based on the types, the market can be segmented into chronic bronchitis and acute bronchitis. Based on the drug class, the market can be segmented into antibiotics, anti-inflammatory drugs, bronchodilators, and mucolytic. Based on the distribution channel, the market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Geographically, the bronchitis treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Key Players Covered:

The major companies in the global bronchitis treatment report include Dr. Reddy's Laboratories Ltd, Pfizer Inc., Sanofi, MELINTA THERAPEUTICS, INC., Pfizer Inc., GlaxoSmithKline plc., Johnson & Johnson Services, Inc., Novartis AG, and other prominent players.

Key Insights:

• New Drug Launch


• Prevalence of Bronchitis for Key Countries


• Recent Bronchitis Treatment Research & Development Activities


• Key Industry Developments - Mergers, Acquisitions, and Partnerships

Regional Analysis:

Geographically, the global bronchitis treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounts for a significant share of the global bronchitis treatment market owing to the high prevalence of bronchitis, awareness regarding health among people, and well-established healthcare infrastructure and facilities. Europe is expected to hold the second-largest share of the market. The growth of the market in this region is due to the increased prevalence of chronic diseases, increasing healthcare expenditure by the European Commission, and rising awareness in people regarding health. However, the Asia-Pacific region is expected to hold the enormous potential to show considerable market growth during the forecast period. This growth in the region can be attributed to the increasing trend of smoking in the young generation, rising prevalence of chronic illness, the growing geriatric population in the region, escalation in the air pollution, and increase in the healthcare expenditure and facilities. Latin America and the Middle East & Africa are increasing steadily in the market.

To gain extensive insights into the market, Request for Customization

Segmentation

Bronchitis Treatment Market Industry Developments

• July 2018 GlaxoSmithKline plc announced the outcome of the Pulmonary Allergy Drugs Advisory Committee of the United States (US) Food and Drug Administration (FDA) meeting on the use of mepolizumab as an add-on treatment to inhaled corticosteroid-based maintenance treatment for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD) guided by blood eosinophil counts.


• In February 2020, Pfizer Inc. announced to continue the trial of azithromycin sr for the treatment of acute bronchitis and secondary infection of chronic respiratory diseases